Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) traded up 4.5% during trading on Wednesday . The stock traded as high as $1,292.65 and last traded at $1,280.6160. 4,402,831 shares traded hands during trading, an increase of 41% from the average session volume of 3,111,745 shares. The stock had previously closed at $1,225.73.
Eli Lilly and Company News Summary
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Lilly will collaborate with Boston-based biotech company Chai Discovery to develop an RNA vaccine platform. The partnership could expand Lilly’s long-term technology and vaccine pipeline, although financial details and near-term revenue implications were not disclosed. Lilly to work with Boston-based firm to develop RNA vaccine platform
- Positive Sentiment: Analyst enthusiasm remains strong, with Lilly identified as a leading candidate among stocks expected to deliver substantial earnings growth. This supports the bullish investment narrative surrounding its obesity and diabetes medicines. These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Eli Lilly Tops Buy Point
- Positive Sentiment: Reports that Lilly’s obesity treatments are outpacing Novo Nordisk strengthen expectations for continued market-share gains. Investors are also watching the developing race in oral GLP-1 treatments, which could create another major growth opportunity beyond injectable medicines. Eli Lilly’s obesity treatments outpace Novo Nordisk
- Positive Sentiment: Lilly completed a Phase 2b study of a treatment for hidradenitis suppurativa, adding depth to its immunology pipeline. The update is potentially supportive for the stock, though investors will need efficacy and regulatory data before assigning meaningful value. Eli Lilly Completes Mid-Stage Hidradenitis Suppurativa Trial, Adding Depth to Its Immunology Pipeline
- Neutral Sentiment: Several early- and late-stage study updates involving LY4178256, eloralintide, mirikizumab, lebrikizumab, dulaglutide, and other immunology programs indicate ongoing pipeline progress, but the announcements did not provide results likely to materially change near-term earnings expectations.
- Neutral Sentiment: Speculation that Lilly could announce a stock split reflects its high per-share price and strong appreciation. A split would improve trading accessibility but would not change the company’s intrinsic value or market capitalization. Stock Split Watch: Is Eli Lilly (LLY) Stock Next?
Analyst Upgrades and Downgrades
Several research firms have weighed in on LLY. Citigroup increased their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Morgan Stanley restated an “overweight” rating and set a $1,419.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 6th. Weiss Ratings lowered Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, August 11th. Berenberg Bank lifted their price target on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a “hold” rating in a report on Monday, June 22nd. Finally, UBS Group set a $1,376.00 price target on Eli Lilly and Company in a research note on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,292.18.
Eli Lilly and Company Stock Up 0.8%
The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The stock has a market cap of $1.18 trillion, a P/E ratio of 42.08, a P/E/G ratio of 1.51 and a beta of 0.51. The stock’s fifty day simple moving average is $1,177.74 and its 200-day simple moving average is $1,058.43.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same quarter in the prior year, the business posted $6.31 EPS. The business’s revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 36.35 earnings per share for the current fiscal year.
Eli Lilly and Company Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 23.22%.
Insider Buying and Selling at Eli Lilly and Company
In related news, CAO Donald A. Zakrowski sold 2,000 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president owned 11,875 shares in the company, valued at $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock valued at $15,958,170 in the last three months. Corporate insiders own 0.14% of the company’s stock.
Institutional Trading of Eli Lilly and Company
Large investors have recently made changes to their positions in the company. Osbon Capital Management LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth $25,000. Basso Capital Management L.P. acquired a new position in Eli Lilly and Company during the fourth quarter worth about $30,000. Maseco LLP raised its stake in Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after acquiring an additional 28 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. lifted its holdings in shares of Eli Lilly and Company by 342.9% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after acquiring an additional 24 shares during the last quarter. Finally, Aventus Investment Advisors Inc. boosted its stake in shares of Eli Lilly and Company by 270.0% in the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock valued at $34,000 after purchasing an additional 27 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.
About Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Featured Stories
- Five stocks we like better than Eli Lilly and Company
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
